Galapagos NV

578 articles with Galapagos NV

• Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

  2/27/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohn’s and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023.

• Galapagos announces full year 2022 results and outlook for 2023

  2/23/2023

  Galapagos NV reports 2022 results, supported by strong adoption of Jyseleca® across Europe, and provides outlook for 2023.

• Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

  2/9/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the European Society for Blood and Marrow Transplantation(EBMT)-European Hematology Association (EHA)5thEuropean CAR T-cell Meeting in Rotterdam.

• Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

  2/8/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) today announced the topline results from DIVERSITY, a global Phase 3 trial to evaluate the safety and efficacy of filgotinib,100mg or 200mg once daily, during induction and maintenance treatment ofbiologic-naïve and biologic-experienced patients with moderate to severe Crohn's disease (CD).

• Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Galapagos NV will participate in the 41th Annual J.P. Morgan Healthcare Conference on January 9-12, 2023.

• Galapagos announces changes to Executive Committee

  12/22/2022

  Galapagos NV announced changes in the Executive Committee effective 1 January 2023.

• Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

  12/13/2022

  Galapagos NV and CellPoint presented encouraging initial data from the ongoing ATALANTA-1 Phase 1/2 study with GLPG5101 at the 64th Annual American Society of Hematology Congress taking place in New Orleans, Louisiana, from 10-13 December.

• Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

  11/11/2022

  Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders.

• Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

  11/8/2022

  Galapagos NV will present new dataon filgotinibat the American College of Rheumatology Convergence 2022 meetingtaking place in Philadelphia, Pennsylvania from 10-14 November 2022.

• 

  Galapagos Turfs Fibrosis, Kidney Disease Focus in “Forward Faster” Plan

  11/4/2022

  Galapagos' new "forward faster" strategy will see the departure of the company’s fibrosis and kidney disease programs and 200 staff members.

• Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

  11/4/2022

  Galapagos NV held its R&D Day 2022, featuring presentations of key opinion leaders and company management on the strategic, scientific, and commercial progress at the company.

• Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

  11/3/2022

  Galapagos NV announced its strategy for accelerated growth and value creation, its financial results for the first nine months of 2022, and theoutlook for the remainder of 2022.

• Galapagos to host its R&D Update 2022 in New York on 4 November 2022

  10/17/2022

  Galapagos NV announced that it will host its R&D Day 2022 for analysts, investors and financial press on Friday, 4 November2022.

• Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress

  10/6/2022

  Galapagos NV (Euronext & NASDAQ: GLPG) will present data at the United European Gastroenterology(UEG)Week2022,taking place from8-11 October 2022. Several Galapagos driven presentationswill be showcased, including new post hoc analyses of the SELECTION study, which investigated the safety and efficacy of Jyseleca®(filgotinib).

• Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

  10/3/2022

  Galapagos NV announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’s Type II variation application for Jyseleca®, a once-daily, oral, JAK1 preferential inhibitor, to amend the European label regarding testicular function after treatment of patients with inflammatory bowel disease and rheumatic conditions.

• Galapagos to present at upcoming investor conferences - Aug 24, 2022

  8/24/2022

  Galapagos NV announced that management will participate in the following upcoming investor conferences:

• 

  Galapagos Dives Into Cell Therapy with CellPoint & AboundBio Acquisitions

  6/22/2022

  ​​​​​​​Galapagos announced that it had acquired CellPoint and AboundBio in an all-cash transaction, greatly expanding its drug portfolio.

• Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

  6/21/2022

  Galapagos NV (Euronext & NASDAQ: GLPG), CellPoint and AboundBiotoday announced that both companies have entered into definitive agreements with Galapagos, propelling Galapagosinto next-generation cell therapywhile significantly broadening itsportfolio and capabilities.

• Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress

  5/25/2022

  Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark.

• Galapagos demonstrates regulatory and commercial progress in Q1 2022

  5/5/2022

  Galapagos NV announced its first quarter 2022financial results, a year-to-date business updateand its outlook for the remainder of 2022.